Mohsin Ahmad, MD
Family Medicine · Norman, OKNPI 1700127917
Payments from drug & device makers
Across 420 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$854
- GSK$811
- Pfizer$780
- AbbVie$652
- Novo Nordisk$529
- Lilly USA, LLC$499
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,76199%
- Education$821%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $854 |
| GSK | 59 | $811 |
| Pfizer | 60 | $780 |
| AbbVie | 24 | $652 |
| Novo Nordisk | 43 | $529 |
| Lilly USA, LLC | 48 | $499 |
| Amgen | 26 | $403 |
| Astellas Pharma US Inc | 16 | $392 |
| Sanofi-aventis U.S. LLC | 11 | $203 |
| Boehringer Ingelheim | 13 | $201 |
| Sumitomo Pharma America, Inc. | 8 | $190 |
| Otsuka America Pharmaceutical, Inc. | 7 | $166 |
| Exact Sciences | 7 | $130 |
| Merck | 8 | $125 |
| Shield Therapeutics Inc | 3 | $125 |
| Phathom Pharmaceuticals, Inc. | 7 | $115 |
| Dexcom, Inc. | 5 | $109 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $77 |
| Axsome Therapeutics, Inc. | 3 | $66 |
| Amarin Pharma, Inc. | 4 | $65 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Abbott | 2 | $33 |
| Corium, LLC | 1 | $29 |
| Shire North American Group Inc | 2 | $26 |
| Pulmonx Corporation | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Johnson & Johnson | 2 | $24 |
| Optinose US, Inc. | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $23 |
| Novartis | 1 | $22 |
| Insulet Corporation | 1 | $20 |
| Viatris Specialty LLC | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Nalpropion Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,842 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 291 | $338,127 |
| OzempicSemaglutide | 90 | $104,725 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 139 | $100,994 |
| EliquisApixaban | 78 | $88,851 |
| JardianceEmpagliflozin | 55 | $79,414 |
| FarxigaDapagliflozin Propanediol | 55 | $59,254 |
| MyrbetriqMirabegron | 64 | $48,271 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 60 | $44,084 |
| TrulicityDulaglutide | 23 | $36,265 |
| JanuviaSitagliptin Phosphate | 20 | $29,467 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $28,404 |
| LinzessLinaclotide | 23 | $23,679 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $19,296 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $15,042 |
| Repatha SureclickEvolocumab | 13 | $11,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $499 | $374,391314 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $854 | $113,793142 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $811 | $108,425169 claims |
| Novo NordiskOzempic | $529 | $104,72590 claims |
| PfizerEliquis, Premarin | $780 | $94,54890 claims |
| Boehringer IngelheimJardiance | $201 | $79,41455 claims |
| Astellas Pharma US IncMyrbetriq | $392 | $48,27164 claims |
| MerckJanuvia, Belsomra | $125 | $38,69941 claims |
| AbbVieLinzess | $652 | $23,67923 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $203 | $8,34411 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $190 | $8,30515 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $3,316415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Norman
- Lisa ConneryNorman$15.6M
- Steven CoxNorman$6.9M
- Rachel AndersonNorman$2.8M
- Carl GriffinOklahoma City$28.2M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Alexander FrankOklahoma City$3.1M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.